Idorsia Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Idorsia de 67.3% y 21.6% respectivamente, mientras que el BPA crecerá en un 67.1% al año.
Información clave
67.3%
Tasa de crecimiento de los beneficios
67.08%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 22.3% |
| Tasa de crecimiento de los ingresos | 21.6% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 19 Jun 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Jun 26
IDIA: Pharmakon Debt Will Likely Constrain Long-Term Upside Potential
Analysts recently lifted their price target on Idorsia stock from CHF 4.00 to CHF 4.50, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What’s in the News for Idorsia Idorsia confirmed the closing of a senior secured term loan of up to CHF 250 million with funds managed by Pharmakon Advisors.
Actualización de narrativa • Jun 05
IDIA: Pediatric Sleep And Vaccine Pipeline Will Support Future Upside Despite Higher Costs
Analysts have lowered their price target on Idorsia to CHF 5, down from CHF 6. They cite reduced forward visibility and higher operating expenses as the main reasons for this adjustment.Actualización de narrativa • May 04
IDIA: Pediatric And Fabry Pipelines Will Support Future Upside Despite Higher Costs
Analysts have reduced their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the main reasons for the change. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares even after the price target move to CHF 5, which signals that they still see potential upside from current levels.Actualización de narrativa • Apr 18
IDIA: Fabry And Pediatric Programs Will Drive Future Upside Despite Higher Costs
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent commentary points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern about execution risks and spending.Actualización de narrativa • Apr 04
IDIA: Fabry Pipeline Progress Will Continue To Drive Future Upside
Analysts have trimmed their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts are still assigning upside potential to Idorsia shares even after the target reset to CHF 5, which signals that they see value at current levels despite near term headwinds.Actualización de narrativa • Mar 20
IDIA: Fabry And Resistant Hypertension Progress Will Continue To Drive Future Upside
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent research points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern around execution and cost control.Actualización de narrativa • Mar 05
IDIA: Fabry And Resistant Hypertension Progress Will Likely Drive Future Upside
Analysts have revised their CHF price targets for Idorsia to reflect updated assumptions for discount rates, revenue growth, profit margins and future P/E. They are now presenting a more balanced view of the company’s risk and earnings potential.Actualización de narrativa • Feb 19
IDIA: Fabry And Hypertension Pipeline Advances Will Likely Drive Future Upside
Analysts have adjusted their CHF price target on Idorsia based on updated assumptions around discount rates, revenue, profit margins, and a higher expected future P/E multiple, resulting in a revised valuation framework in CHF terms. What's in the News Idorsia outlined an FDA-agreed Phase 3 registration program for lucerastat in Fabry disease, centered on kidney pathology and including a pivotal biopsy study plus a second trial comparing oral therapy with current standard-of-care to support a potential market authorization pathway (Key Developments).Actualización de narrativa • Feb 04
IDIA: Hypertension And Insomnia Pipeline Progress Will Likely Drive Future Upside
Analysts have trimmed their price target on Idorsia to reflect a slightly lower profit margin outlook and a higher assumed future P/E of 31.60x, while keeping their fair value estimate broadly unchanged. What's in the News Idorsia signed an exclusive license and supply agreement with EMS S.A. to bring QUVIVIQ (daridorexant) to patients across Latin America.Actualización de narrativa • Jan 21
IDIA: Hypertension And Insomnia Franchise Will Likely Drive Future Upside
Analysts have adjusted their price target on Idorsia slightly lower to reflect updated assumptions around fair value, a modestly higher discount rate, more conservative revenue growth expectations, a similar profit margin outlook, and a higher future P/E multiple. What's in the News Publication of Phase 3 MODIFY and open label extension data for lucerastat in Fabry disease, with results in Nature Communications highlighting sustained biomarker reductions and signals on renal and cardiac function in a small patient population.Actualización de narrativa • Jan 07
IDIA: Hypertension And Insomnia Assets Will Likely Drive Future Upside
Analysts have kept their price target for Idorsia broadly unchanged. They cite only small tweaks to inputs such as a slightly higher discount rate, steady revenue growth and profit margin assumptions, and a marginally adjusted future P/E multiple as the basis for their updated view.Artículo de análisis • Dec 22
Idorsia Ltd (VTX:IDIA) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Idorsia Ltd ( VTX:IDIA ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. The...Actualización de narrativa • Dec 17
IDIA: Hypertension And Insomnia Portfolio Will Likely Deliver Upside From Current Levels
Analysts have raised their price target for Idorsia significantly, citing a higher fair value estimate of 5.0 dollars, stronger anticipated revenue growth, and an expectation of a materially higher future price to earnings multiple, partially offset by a slightly lower discount rate. What's in the News Idorsia reaffirmed 2025 guidance, targeting around CHF 130 million in QUVIVIQ net sales and a US-GAAP operating loss of about CHF 55 million for the global business, supported by approximately CHF 165 million EBIT from partnered activities (corporate guidance).Actualización de narrativa • Dec 03
IDIA: Hypertension And Insomnia Portfolio Will Likely Fail To Justify Current Price
Analysts have modestly raised their price target on Idorsia, citing a slightly lower perceived risk profile and a marginally stronger long term profit outlook that supports a small increase in fair value, now estimated at approximately 2.00. What's in the News Reaffirmed 2025 guidance, projecting QUVIVIQ net sales around CHF 130 million, partnered business US-GAAP EBIT of about CHF 165 million, and a global US-GAAP operating loss of roughly CHF 55 million, mainly driven by the amended Viatris deal (corporate guidance).Actualización de narrativa • Nov 19
IDIA: Limited Near-Term Upside Expected Despite Recent Price Reassessment
Narrative Update on Idorsia Analysts have raised their price target for Idorsia, doubling it from CHF 1 to CHF 2. This change is attributed to improved outlooks in key financial metrics, including a slightly lower discount rate and stable revenue growth projections.Artículo de análisis • Nov 07
Little Excitement Around Idorsia Ltd's (VTX:IDIA) Revenues As Shares Take 29% Pounding
The Idorsia Ltd ( VTX:IDIA ) share price has softened a substantial 29% over the previous 30 days, handing back much of...Actualización de narrativa • Nov 03
IDIA: Near-Term Risks Will Likely Limit Upside Despite Price Target Lift
Analysts have increased their price target for Idorsia by CHF 1.00 to CHF 2.00. They cite improved revenue growth projections and a more favorable future price-to-earnings outlook, despite a slightly higher discount rate and modestly lower profit margin expectations.Actualización de narrativa • Sep 23
Global Expansion And FDA Review Will Moderate Overvaluation
Despite a decline in revenue growth forecasts, the significant rise in Idorsia’s future P/E multiple underpins the sharp increase in its consensus analyst price target from CHF2.00 to CHF4.00. What's in the News Simcere Pharmaceuticals launched QUVIVIQ (daridorexant), Idorsia's dual orexin receptor antagonist for insomnia, in China, with approval highlighting its differentiated clinical profile and lack of psychotropic labeling.Artículo de análisis • Sep 14
Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Idorsia Ltd ( VTX:IDIA ) shares have continued their recent momentum with a 38% gain in the last month alone. The...Nueva narrativa • Sep 08
Global Expansion And FDA Review Will Moderate Overvaluation
Key Takeaways Market optimism for rapid revenue growth may be premature, with unvalidated access, uncertain drug uptake, and regulatory outcomes adding risk to earnings expectations. Longer-term valuation appears inflated by pipeline commercialization hopes, while rising costs and increasing pricing scrutiny threaten future margins and profitability.Artículo de análisis • Aug 24
New Forecasts: Here's What Analysts Think The Future Holds For Idorsia Ltd (VTX:IDIA)
Shareholders in Idorsia Ltd ( VTX:IDIA ) may be thrilled to learn that the covering analyst has just delivered a major...Artículo de análisis • Jul 19
There's Reason For Concern Over Idorsia Ltd's (VTX:IDIA) Massive 46% Price Jump
Despite an already strong run, Idorsia Ltd ( VTX:IDIA ) shares have been powering on, with a gain of 46% in the last...Artículo de análisis • Dec 19
Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified
Idorsia Ltd ( VTX:IDIA ) shareholders are no doubt pleased to see that the share price has bounced 71% in the last...Artículo de análisis • Nov 06
One Idorsia Ltd (VTX:IDIA) Analyst Has Been Cutting Their Forecasts
The latest analyst coverage could presage a bad day for Idorsia Ltd ( VTX:IDIA ), with the covering analyst making...Artículo de análisis • Nov 04
Market Cool On Idorsia Ltd's (VTX:IDIA) Revenues Pushing Shares 33% Lower
To the annoyance of some shareholders, Idorsia Ltd ( VTX:IDIA ) shares are down a considerable 33% in the last month...Artículo de análisis • Sep 18
Take Care Before Jumping Onto Idorsia Ltd (VTX:IDIA) Even Though It's 25% Cheaper
The Idorsia Ltd ( VTX:IDIA ) share price has fared very poorly over the last month, falling by a substantial 25%. For...Artículo de análisis • May 30
Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company
Idorsia Ltd ( VTX:IDIA ) shareholders would be excited to see that the share price has had a great month, posting a 26...Artículo de análisis • May 26
Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year
The latest analyst coverage could presage a bad day for Idorsia Ltd ( VTX:IDIA ), with the analysts making...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 687 | 176 | N/A | N/A | 2 |
| 12/31/2027 | 272 | -69 | N/A | N/A | 3 |
| 12/31/2026 | 220 | -112 | N/A | N/A | 3 |
| 3/31/2026 | 219 | -221 | -134 | -119 | N/A |
| 12/31/2025 | 221 | -112 | -167 | -153 | N/A |
| 9/30/2025 | 233 | -118 | -133 | -121 | N/A |
| 6/30/2025 | 217 | -133 | -263 | -251 | N/A |
| 3/31/2025 | 161 | -230 | -330 | -313 | N/A |
| 12/31/2024 | 113 | -264 | -388 | -370 | N/A |
| 9/30/2024 | 74 | -296 | -488 | -470 | N/A |
| 6/30/2024 | 128 | 29 | -422 | -403 | N/A |
| 3/31/2024 | 141 | -56 | -504 | -498 | N/A |
| 12/31/2023 | 152 | -298 | -639 | -629 | N/A |
| 9/30/2023 | 185 | -374 | -751 | -739 | N/A |
| 6/30/2023 | 126 | -814 | -874 | -859 | N/A |
| 3/31/2023 | 113 | -843 | -889 | -871 | N/A |
| 12/31/2022 | 97 | -828 | -886 | -859 | N/A |
| 9/30/2022 | 48 | -887 | -868 | -836 | N/A |
| 6/30/2022 | 44 | -810 | -788 | -756 | N/A |
| 3/31/2022 | 34 | -728 | -719 | -678 | N/A |
| 12/31/2021 | 35 | -635 | -621 | -590 | N/A |
| 9/30/2021 | 36 | -520 | -542 | -515 | N/A |
| 6/30/2021 | 27 | -499 | -513 | -491 | N/A |
| 3/31/2021 | 74 | -429 | -419 | -409 | N/A |
| 12/31/2020 | 72 | -445 | -374 | -365 | N/A |
| 9/30/2020 | 70 | -450 | -379 | -367 | N/A |
| 6/30/2020 | 69 | -451 | -417 | -400 | N/A |
| 3/31/2020 | 22 | -507 | -478 | -459 | N/A |
| 12/31/2019 | 24 | -494 | N/A | -462 | N/A |
| 9/30/2019 | 61 | -460 | N/A | -461 | N/A |
| 6/30/2019 | 61 | -459 | N/A | -430 | N/A |
| 3/31/2019 | 61 | -414 | N/A | -391 | N/A |
| 12/31/2018 | 61 | -386 | N/A | -353 | N/A |
| 9/30/2018 | 209 | -213 | N/A | -63 | N/A |
| 6/30/2018 | 203 | -165 | N/A | -25 | N/A |
| 12/31/2017 | 190 | -17 | N/A | 115 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que IDIA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (0.6%).
Beneficios vs. Mercado: Se prevé que IDIA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que IDIA sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (21.6% al año) de IDIA crezcan más rápidamente que los del mercado Swiss (4.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (21.6% al año) de IDIA crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de IDIA se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/29 15:04 |
| Precio de las acciones al final del día | 2026/06/26 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Idorsia Ltd está cubierta por 10 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rosie Turner | Barclays |
| Alistair Campbell | Berenberg |
| Sachin Jain | BofA Global Research |